Abstract
Exopolysaccharides (EPSs) are carbohydrate polymers that are synthesized and present on the surface of bifidobacteria. Due to their potential applications in diverse sectors, such as food, biotechnology, cosmetics, and medicine, EPSs synthesized by bifidobacteria have recently attracted more attention. EPS production not only has benefits in food and health but also has effects on probiotics in the microbial ecosystem. In this study, we investigated the interaction between bifidobacteria EPSs and human gut microbiota in vitro using thin-layer chromatography, 16S rDNA high-throughput sequencing, and gas chromatography. The results showed that human gut microbiota has the capacity to degrade EPSs, although the degradation rate was approximately 50% after fermenting for 48 h. On the other hand, EPSs regulate the human gut microbiota. Fermented samples in the VI_Bif group clustered together according to the bacterial community compared to the VI_Starch group, in which starch was added as a carbon source. The bifidobacteria EPS promoted the growth of phylum Deinococcus_Thermus, class Deinococci, order Deinococcales, and genus Coprococcus. EPSs also increased the production of propionic acid compared to the starch group. The detection results of Dionex ICS 5000 high-purity capillary ion chromatography system showed that EPSs had absorption peaks of fucose, rhamnose, galactose/acetyl glucosamine, glucose, and ribose, and the molecular proportion of these monosaccharides was approximately 2: 2: 440: 3: 53. The monosaccharide composition of this EPS appears to be more complex than previously reported for bifidobacteria EPS. Additional studies are needed to elucidate its structure and functions.
Similar content being viewed by others
References
Allen AP, Dinan TG, Clarke G, Cryan JF (2017) A psychology of the human brain-gut-microbiome axis. Soc Personal Psychol Compass 11:e12309
Arboleya S, Watkins C, Stanton C, Ross RP (2016) Gut bifidobacteria populations in human health and aging. Front Microbiol 7:1204
Arora T, Backhed F (2016) The gut microbiota and metabolic disease: current understanding and future perspectives. J Intern Med 280:339–349
Bron PA, van Baarlen P, Kleerebezem M (2011) Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 10:66–78
Cole JR, Wang Q, Cardenas E, Fish J, Chai B, Farris RJ, Kulam-Syed-Mohideen AS, McGarrell DM, Marsh T, Garrity GM, Tiedje JM (2009) The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res 37:D141–D145
Coombes JL, Powrie F (2008) Dendritic cells in intestinal immune regulation. Nat Rev Immunol 8:435–446
Dennis KL, Wang Y, Blatner NR, Wang S, Saadalla A, Trudeau E, Roers A, Weaver CT, Lee JJ, Gilbert JA, Chang EB, Khazaie K (2013) Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Res 73:5905–5913
Duffy LC, Zielezny MA, Riepenhoff-Talty M, Dryja D, Sayahtaheri-Altaie S, Griffiths E, Ruffin D, Barrett H, Ogra PL (1994a) Reduction of virus shedding by B. bifidum in experimentally induced MRV infection. Statistical application for ELISA. Dig Dis Sci 39:2334–2340
Duffy LC, Zielezny MA, Riepenhoff-Talty M, Dryja D, Sayahtaheri-Altaie S, Griffiths E, Ruffin D, Barrett H, Rossman J, Ogra PL (1994b) Effectiveness of Bifidobacterium bifidum in mediating the clinical course of murine rotavirus diarrhea. Pediatr Res 35:690–695
Freitas F, Alves VD, Reis MA (2011) Advances in bacterial exopolysaccharides: from production to biotechnological applications. Trends Biotechnol 29:388–398
Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H, Hattori M, Ohno H (2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469:543–547
Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58:1509–1517
Gerhardt S, Mohajeri MH (2018) Changes of colonic bacterial composition in Parkinson’s disease and other neurodegenerative diseases. Nutrients 10(6):E708
Gueimonde M, Margolles A, de los Reyes-Gavilan CG, Salminen S (2007) Competitive exclusion of enteropathogens from human intestinal mucus by Bifidobacterium strains with acquired resistance to bile--a preliminary study. Int J Food Microbiol 113:228–232
Hidalgo-Cantabrana C, Lopez P, Gueimonde M, de Los Reyes-Gavilan CG, Suarez A, Margolles A, Ruas-Madiedo P (2012) Immune modulation capability of exopolysaccharides synthesised by lactic acid bacteria and bifidobacteria. Probiotics Antimicrob Proteins 4:227–237
Hidalgo-Cantabrana C, Sanchez B, Milani C, Ventura M, Margolles A, Ruas-Madiedo P (2014) Genomic overview and biological functions of exopolysaccharide biosynthesis in Bifidobacterium spp. Appl Environ Microbiol 80:9–18
Hosono A, Lee J, Ametani A, Natsume M, Hirayama M, Adachi T, Kaminogawa S (1997) Characterization of a water-soluble polysaccharide fraction with immunopotentiating activity from Bifidobacterium adolescentis M101-4. Biosci Biotechnol Biochem 61:312–316
Lebeer S, Vanderleyden J, De Keersmaecker SC (2010) Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 8:171–184
Lee IC, Caggianiello G, van S, Taverne N, Meijerink M, Bron PA, Spano G, Kleerebezem M (2016) Strain-specific features of extracellular polysaccharides and their impact on Lactobacillus plantarum-host interactions. Appl Environ Microbiol 82:3959–3970
Lei F, Yin Y, Wang Y, Deng B, Yu HD, Li L, Xiang C, Wang S, Zhu B, Wang X (2012) Higher-level production of volatile fatty acids in vitro by chicken gut microbiotas than by human gut microbiotas as determined by functional analyses. Appl Environ Microbiol 78:5763–5772
Liu J, Yang H, Yin Z, Jiang X, Zhong H, Qiu D, Zhu F, Li R (2017) Remodeling of the gut microbiota and structural shifts in preeclampsia patients in South China. Eur J Clin Microbiol Infect Dis 36:713–719
Moslemi M, Mazaheri Nezhad Fard R, Hosseini SM, Homayouni-Rad A, Mortazavian AM (2016) Incorporation of Propionibacteria in fermented milks as a probiotic. Crit Rev Food Sci Nutr 56:1290–1312
O’Callaghan A, van Sinderen D (2016) Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol 7:925
Perdigon G, Alvarez S, Rachid M, Aguero G, Gobbato N (1995) Immune system stimulation by probiotics. J Dairy Sci 78:1597–1606
Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, Tyakht AV, Kovarsky BA, Alekseev DG, Kostryukova ES, Mironova YS, Izhboldina OP, Nikitina MA, Perevozchikova TV, Fait EA, Babenko VV, Vakhitova MT, Govorun VM, Sazonov AE (2017) Analysis of gut microbiota in patients with Parkinson’s disease. Bull Exp Biol Med 162:734–737
Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C (2005) Review article: bifidobacteria as probiotic agents -- physiological effects and clinical benefits. Aliment Pharmacol Ther 22:495–512
Rehm BH (2010) Bacterial polymers: biosynthesis, modifications and applications. Nat Rev Microbiol 8:578–592
Roberts CM, Fett WF, Osman SF, Eijey C, O’Connor JV, Hoover DG (1995) Exopolysaccharide production by Bifidobacterium longum BB-79. J Appl Bacteriol 78:463–468
Ruiz L, Delgado S, Ruas-Madiedo P, Sanchez B, Margolles A (2017) Bifidobacteria and their molecular communication with the immune system. Front Microbiol 8:2345
Russell DA, Ross RP, Fitzgerald GF, Stanton C (2011) Metabolic activities and probiotic potential of bifidobacteria. Int J Food Microbiol 149:88–105
Rycroft CE, Jones MR, Gibson GR, Rastall RA (2001) Fermentation properties of gentio-oligosaccharides. Lett Appl Microbiol 32:156–161
Salazar N, Gueimonde M, Hernandez-Barranco AM, Ruas-Madiedo P, de los Reyes-Gavilan CG (2008) Exopolysaccharides produced by intestinal Bifidobacterium strains act as fermentable substrates for human intestinal bacteria. Appl Environ Microbiol 74:4737–4745
Salazar N, Ruas-Madiedo P, Kolida S, Collins M, Rastall R, Gibson G, de Los Reyes-Gavilan CG (2009) Exopolysaccharides produced by Bifidobacterium longum IPLA E44 and Bifidobacterium animalis subsp. lactis IPLA R1 modify the composition and metabolic activity of human faecal microbiota in pH-controlled batch cultures. Int J Food Microbiol 135:260–267
Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van Horn DJ, Weber CF (2009) Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75:7537–7541
Shen Y, Xu J, Li Z, Huang Y, Yuan Y, Wang J, Zhang M, Hu S, Liang Y (2018) Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: a cross-sectional study. Schizophr Res 197:470–477
van de Guchte M, Blottiere HM, Dore J (2018) Humans as holobionts: implications for prevention and therapy. Microbiome 6:81
Ventura M, Turroni F, Motherway MO, MacSharry J, van Sinderen D (2012) Host-microbe interactions that facilitate gut colonization by commensal bifidobacteria. Trends Microbiol 20:467–476
Wang Q, Garrity GM, Tiedje JM, Cole JR (2007) Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73:5261–5267
Wu MH, Pan TM, Wu YJ, Chang SJ, Chang MS, Hu CY (2010) Exopolysaccharide activities from probiotic Bifidobacterium: Immunomodulatory effects (on J774A.1 macrophages) and antimicrobial properties. Int J Food Microbiol 144:104–110
Xu R, Shang N, Li P (2011) In vitro and in vivo antioxidant activity of exopolysaccharide fractions from Bifidobacterium animalis RH. Anaerobe 17:226–231
Yang L, Bian G, Su Y, Zhu W (2014) Comparison of faecal microbial community of lantang, bama, erhualian, meishan, xiaomeishan, duroc, landrace, and yorkshire sows. As-Aust. J Anim Sci 27:898–906
Zhang Z, Xie J, Zhang F, Linhardt RJ (2007) Thin-layer chromatography for the analysis of glycosaminoglycan oligosaccharides. Anal Biochem 371:118–120
Acknowledgments
The authors would like to thank LetPub (www.letpub.com) for providing linguistic assistance during the preparation of this manuscript.
Funding
This study was funded by the Key Research and Development Plan of Zhejiang Province (2017C02G4010648), the Hunan Natural Science Foundation (No. 2018JJ3200), and the National Nature Science Foundation of China (No. 31741109).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Zhejiang Gongshang University research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(PDF 940 kb)
Rights and permissions
About this article
Cite this article
Liu, G., Chen, H., Chen, J. et al. Effects of bifidobacteria-produced exopolysaccharides on human gut microbiota in vitro. Appl Microbiol Biotechnol 103, 1693–1702 (2019). https://doi.org/10.1007/s00253-018-9572-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-018-9572-6